To evaluate the efficacy and safety of Prospekta in the treatment of asthenic syndrome in young and middle-aged patients with subjective cognitive impairment.
Material and methods
We selected 60 patients aged 20-50 years with asthenia and complaints of cognitive decline. Patients were treated with Prospekta 1 tablet twice a day for 4 weeks. At baseline and after treatment, we evaluated asthenia by the MFI-20 scale (The Multidimensional Fatigue Inventory-20), cognitive functions by the Stroop and Bourdon tests, distress, anxiety, depression, somatization by the 4DSQ questionnaire (The Four-Dimensional Symptom Questionnaire), reaction switching speed by computer testing based on the Stenberg paradigm using videooculography. Concomitant diseases and therapy were recorded. The safety of treatment with Prospekta was evaluated.
Fifty five patients (41 females, mean age 38,5 years) were included in the analyses. Prospekta significantly reduced the severity of asthenia and its components on the MFI-20 scale (p<0,001), increased the speed of attention switching according to the Stroop test (p<0,001), reduced the level of distress, depression, anxiety and somatization according to the 4DSQ questionnaire (p<0,001). There were no serious adverse events and changes in the vital signs.
Prospekta is an effective and safe drug for the treatment of asthenia in young and middle-aged patients with subjective cognitive impairment.
Asthenia, young, middle age, cognitive impairment, оbservational non-intervention study, Prospekta.